Johnson & Johnson’s pullback from RSV research thins the pack of companies aiming to develop a vaccine for the pathogen. GSK and Pfizer have vaccines under FDA review and a shot from Moderna could soon follow.
The conference highlights the convergence of digital health and drug development. Among the panel discussions are a focus on the state of AI in drug discovery and the future of digital medicines. A startup pitch contest spotlights companies seeking to improve clinical trials. Register for free today!
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.
Some candor from the director of global regulatory affairs at Janssen Research & Development, as she touched on contracting with CROs: “They’ll screw you in a heartbeat.” Clinical research organizations are a fine option (and sometimes the only one) for small life sciences companies attempting to push their product through the regulatory pipeline – but often it’s a matter of […]
In another move to potentially beef up its Alzheimer’s pipeline, Johnson & Johnson has struck a drug development deal with one of the companies located at its innovation lab in San Francisco. J&J’s Innovation Center and San Francisco drug startup Alector announced today a deal under which Janssen will fund early R&D efforts for one […]
The life science industry has been warming up to the use of health IT and digital health tools to improve clinical trials. Remote monitoring, adherence tools and ways to make clinical trial design easier are a few of the areas that have gotten attention. The goal is to cut the time it takes to set […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Despite a major setback last summer when its promising drug bapineuzumab failed in late-stage clinical trials, Janssen Pharmaceuticals is looking to beef up its Alzheimer’s disease drug pipeline in a new deal with Evotec AG. Drug discovery company Evotec has a proprietary database of genes that are dysregulated in Alzheimer’s patients, as discovered in the […]
An RNAi delivery startup that’s been keeping a low profile has emerged with the announcement of a completed seed funding round and acceptance to Janssen Labs. MedCity News learned in April that Arcturus Therapeutics was raising a $1.3 million round. The company now says it’s completed the round, which it will use to support the […]
An application for a higher dosage of an FDA-approved HIV drug from Janssen Pharmaceuticals has been turned down by the U.S. Food and Drug Administration, according to a company statement. The complete response letter was for an 800 milligram dose of Prezista, a protease inhibitor. The Titusville, New Jersey company, the Pharmaceutical Division of Johnson […]
Johnson & Johnson (NYSE:JNJ) subsidiary Janssen Pharamceuticals’ drug Xarelto, an anticoagulant that has produced positive phase 3 results to treat clots in the lung in a recent study, could set the standard for a new generation of anticoagulant drugs. In the study of 4,833 patients, Xarelto was demonstrated to be comparable to patients taking warfarin […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.